Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00129753

Recruitment Status : Withdrawn (Terminated due to slow accrual.)

First Posted : August 12, 2005

Last Update Posted : November 8, 2018

Sponsor:

Information provided by:

M.D. Anderson Cancer Center

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Actual Primary Completion Date :	September 5, 2006
Actual Study Completion Date :	September 5, 2006

To Top